PROFOUND MEDICAL CORP (PROF) Stock Price & Overview
NASDAQ:PROF • CA74319B5027
Current stock price
The current stock price of PROF is 5.32 USD. Today PROF is up by 5.14%. In the past month the price decreased by -27.3%. In the past year, price decreased by -25.7%.
PROF Key Statistics
- Market Cap
- 193.063M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.41
- Dividend Yield
- N/A
PROF Stock Performance
PROF Stock Chart
PROF Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PROF. When comparing the yearly performance of all stocks, PROF is a bad performer in the overall market: 87.92% of all stocks are doing better.
PROF Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PROF. The financial health of PROF is average, but there are quite some concerns on its profitability.
PROF Earnings
On March 5, 2026 PROF reported an EPS of -0.27 and a revenue of 5.98M. The company missed EPS expectations (-0.25% surprise) and missed revenue expectations (-18.19% surprise).
PROF Forecast & Estimates
5 analysts have analysed PROF and the average price target is 11.6 USD. This implies a price increase of 117.99% is expected in the next year compared to the current price of 5.32.
For the next year, analysts expect an EPS growth of 23.59% and a revenue growth 101.18% for PROF
PROF Groups
Sector & Classification
PROF Financial Highlights
Over the last trailing twelve months PROF reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS decreased by -25.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.95% | ||
| ROE | -64.08% | ||
| Debt/Equity | 0.07 |
PROF Ownership
PROF Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 18.29 | 183.255B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.1 | 169.761B | ||
| SYK | STRYKER CORP | 22.13 | 128.458B | ||
| BSX | BOSTON SCIENTIFIC CORP | 19.91 | 103.101B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.25 | 47.916B | ||
| IDXX | IDEXX LABORATORIES INC | 39.32 | 45.961B | ||
| BDX | BECTON DICKINSON AND CO | 11.46 | 43.887B | ||
| RMD | RESMED INC | 18.65 | 32.922B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.94 | 31.743B | ||
| DXCM | DEXCOM INC | 26.18 | 25.766B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.38 | 17.192B | ||
| HOLX | HOLOGIC INC | 15.37 | 16.835B | ||
| PODD | INSULET CORP | 35.21 | 15.988B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PROF
Company Profile
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Company Info
IPO: 2014-09-24
PROFOUND MEDICAL CORP
2400 Skymark Ave Unit 6
Mississauga ONTARIO L4W 5K5 CA
CEO: Arun Menawat
Employees: 131
Phone: 16474761350
PROFOUND MEDICAL CORP / PROF FAQ
What does PROF do?
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Can you provide the latest stock price for PROFOUND MEDICAL CORP?
The current stock price of PROF is 5.32 USD. The price increased by 5.14% in the last trading session.
Does PROF stock pay dividends?
PROF does not pay a dividend.
What is the ChartMill rating of PROFOUND MEDICAL CORP stock?
PROF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of PROFOUND MEDICAL CORP (PROF) based on its PE ratio?
PROFOUND MEDICAL CORP (PROF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.41).
Can you provide the number of employees for PROFOUND MEDICAL CORP?
PROFOUND MEDICAL CORP (PROF) currently has 131 employees.
What is PROFOUND MEDICAL CORP worth?
PROFOUND MEDICAL CORP (PROF) has a market capitalization of 193.06M USD. This makes PROF a Micro Cap stock.